Fosun Pharma subsidiary gets clinical trial green light for HLX37

Shanghai Fosun Pharmaceutical Group announced that its controlled subsidiary, Shanghai Henlius Biotech, has received approval from the National Medical Products Administration for clinical trials of HLX37 injection. This recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody is intended for treating patients with advanced/metastatic solid tumors. Henlius plans to commence Phase 1 clinical trials in China under suitable conditions.

HLX37, an independently developed drug by the Fosun Pharma Group, has demonstrated tumor growth inhibition and good safety in preclinical studies. As of October 2025, the cumulative research and development investment for HLX37 by the group amounts to approximately RMB 50.23 million (unaudited).

The announcement notes that PD-1/PD-L1 and VEGF bispecific antibody products generated approximately $0.92 million in global sales in 2024, with the first such product approved globally in May 2024. The company cautioned that drug development is a long-term process with inherent risks, including the potential termination of clinical trials due to safety or efficacy issues.